Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Zealand Pharma clinical trials
The registry lists 43 studies whose lead sponsor is Zealand Pharma. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.
Keep track of what changes. Save the Zealand Pharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Zealand Pharma.
- Zealand Pharma43 studiesSame company
Something wrong?
Focus areas
Conditions Zealand Pharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 43 of 43.
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSRecruitingNCT07197944Phase 3
- A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and ObesityRecruitingNCT07721597Early Phase 1
- A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment PeriodRecruitingNCT07733089Phase 1
- Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionRecruitingNCT07682818Phase 1
- A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy ParticipantsRecruitingNCT06682975Phase 1
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)CompletedNCT06926842Phase 2
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialCompletedNCT04881825Phase 3
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSCompletedNCT03905707Phase 3
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismCompletedNCT03941236Phase 3
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeActive, not recruitingNCT07228403Phase 3
- Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsCompletedNCT07338214Phase 1
- Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesCompletedNCT06662539Phase 2
- Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionCompletedNCT07076030Phase 1
- A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DCompletedNCT05378672Phase 3
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)CompletedNCT03690206Phase 3
- A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of DapiglutideCompletedNCT06758583Phase 1
- A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570TerminatedNCT06000891Phase 1
- Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedNCT04172441Phase 2/3
- The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel SyndromeCompletedNCT04991311Phase 3
- A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy ParticipantsCompletedNCT05613387Phase 1
- A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedNCT03777176Phase 3
- Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsWithdrawnNCT04824872Phase 2
- A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DMCompletedNCT03895697Phase 3
- A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial ParticipantsCompletedNCT05096598Phase 1
- A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570CompletedNCT04612517Early Phase 1
- A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.CompletedNCT04318743Phase 1
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedNCT03667053Phase 3
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedNCT03378635Phase 3
- Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DMCompletedNCT03688711Phase 3
- A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusCompletedNCT03216226Phase 3
- Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationCompletedNCT03735225Phase 1
- Feasibility Trial Testing the Bionic Pancreas With ZP4207CompletedNCT02971228Phase 2
- A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570CompletedNCT03994549Early Phase 1
- Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal FunctionCompletedNCT04178447Phase 1
- Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial InfarctionCompletedNCT01977755Phase 2
- Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy SubjectsCompletedNCT03279302Phase 1
- A Phase 2 Trial Testing ZP1848 in Patients With SBSCompletedNCT02690025Phase 2
- ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonCompletedNCT02916251Phase 2
- Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonCompletedNCT02660008Phase 2
- Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorCompletedNCT02367053Phase 1
- Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207CompletedNCT02390141Phase 1
- Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending DoseCompletedNCT00868660Phase 1
- ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart FailureTerminatedNCT00283361Phase 2